US20070207149A1 - Cancer treatment using viruses and camptothecins - Google Patents

Cancer treatment using viruses and camptothecins Download PDF

Info

Publication number
US20070207149A1
US20070207149A1 US11/568,228 US56822805A US2007207149A1 US 20070207149 A1 US20070207149 A1 US 20070207149A1 US 56822805 A US56822805 A US 56822805A US 2007207149 A1 US2007207149 A1 US 2007207149A1
Authority
US
United States
Prior art keywords
virus
subject
irinotecan
camptothecin compound
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/568,228
Other languages
English (en)
Inventor
Robert Lorence
Michael Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Biologics Corp
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Priority to US11/568,228 priority Critical patent/US20070207149A1/en
Assigned to WELLSTAT BIOLOGICS CORPORATION reassignment WELLSTAT BIOLOGICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LORENCE, ROBERT M., ROBERTS, MICHAEL S.
Publication of US20070207149A1 publication Critical patent/US20070207149A1/en
Assigned to WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT reassignment WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: WELLSTAT BIOLOGICS CORPORATION
Assigned to PDL BIOPHARMA, INC. reassignment PDL BIOPHARMA, INC. SECURITY AGREEMENT Assignors: WELLSTAT BIOLOGICS CORPORATION
Assigned to WELLSTAT BIOLOGICS CORPORATION reassignment WELLSTAT BIOLOGICS CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • camptothecins as anticancer agents is reviewed in Garcia-Carbonero, et al., Clin. Cancer Res. (March 2002) 8: 641-661; and in Pizzolato J F and Saltz L B, The camptothecins. Lancet 2003 361:2235-42. Camptothecins have antitumor activity based on their binding to and inhibition of topoisomerase I, a nuclear enzyme which reduces torsional stress during DNA replication and which has an important role in DNA replication. Topotecan and irinotecan are the two camptothecins have been approved for clinical use by the US Food and Drug Administration (FDA).
  • FDA US Food and Drug Administration
  • camptothecins are in development as cancer therapeutics (Ulukan and Swaan, (Campothecins: a review of their chemotherapeutic potential. Drugs, 2002, 62:2039-57); and Garcia-Carbonero and Supko, 2002).
  • This invention provides a method for treating a mammalian subject having a neoplasm, comprising administering to the subject a virus and a camptothecin compound in a combined amount effective to treat the subject; wherein the virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.
  • the treatment further comprises administering to the subject a monoclonal antibody against epidermal growth factor receptor in an amount effective, in combination with the virus and the camptothecin compound, to treat the subject.
  • This invention provides for the use of a virus and/or a camptothecin compound in the manufacture of a medicament for treating, in combination with the other ingredient mentioned, a subject having a neoplasm; wherein the virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.
  • This invention also provides the use of a monoclonal antibody against epidermal growth factor receptor in the manufacture of a medicament for treating, in combination with a virus as mentioned above and a camptothecin compound, a subject having a neoplasm.
  • This invention is based on the finding that anti-cancer viruses and camptothecins in combination are effective against neoplastic cells.
  • a mesogenic strain of Newcastle disease virus and irinotecan, a camptothecin compound have demonstrated a greater than additive level of in vivo antitumor activity, as shown in the examples.
  • the transitional term “comprising” is open-ended.
  • a claim utilizing this term can contain elements in addition to those recited in such claim.
  • the claims can read on treatment regimens that also include other therapeutic agents or therapeutic virus doses not specifically recited therein, as long as the recited elements or their equivalent are present.
  • NDV Newcastle Disease Virus
  • DLT is an abbreviation for dose limiting toxicity.
  • plaque-forming unit PFU
  • BPFU means billion PFUs.
  • PP plaque-purified.
  • PPMK107 means plaque-purified Newcastle Disease virus strain MK107.
  • PFU/m 2 which is a standard unit for expressing dosages, means PFUs per square meter of patient surface area.
  • replication-competent virus refers to a virus that produces infectious progeny in cancer cells.
  • the virus is replication-competent.
  • the virus when the virus is a Newcastle Disease Virus it can be of low (lentogenic), moderate (mesogenic) or high (velogenic) virulence.
  • the level of virulence is determined in accordance with the Mean Death Time in Eggs (MDT) test.
  • MDT Mean Death Time in Eggs
  • Viruses are classified by the MDT test as lentogenic (MDT>90 hours); mesogenic (MDT from 60-90 hours); and velogenic (MDT ⁇ 60 hours).
  • Mesogenic NDV is currently preferred.
  • any conventional route or technique for administering viruses to a subject can be utilized.
  • routes of administration refer to WO 00/62735.
  • the virus is administered systemically, for example intravenously.
  • the virus is a mesogenic strain of Newcastle Disease Virus.
  • from 12 ⁇ 10 9 to 120 ⁇ 10 9 PFUI/m 2 per dose of a mesogenic strain of Newcastle Disease virus is administered intravenously to a human subject, more preferably from 12 ⁇ 10 9 to 48 ⁇ 10 9 PFU/m 2 per dose.
  • mg/m 2 means milligrams per square meter of patient surface area.
  • the picornavirus is a poliovirus, an echovirus, or a coxsackievirus.
  • coxsackieviruses that are suitable in accordance with this invention include the following types: A21, A13, A15 and A18.
  • suitable echoviruses include echovirus type 1.
  • camptothecin compound means that class of compounds considered to be camptothecins, camptothecin analogs, camptothecin derivatives or camptothecin conjugates. These compounds are based on the characteristic five-ring backbone of camptothecin:
  • camptothecin compounds include irinotecan (CAMPTOSAR; 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin), topotecan (HYCAMPTIN; (S)-9-N;N-dimethylaminoethyl-10-hydroxycamptothecin), 9-aminocamptothecin (9-amino-20(S)-camptothecin), 9-nitrocamptothecin (also called rubitecan), lurtotecan (7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin), exatecan, karenitecin, and a homocamptothecin.
  • CAMPTOSAR 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin
  • topotecan HYCAMPTIN
  • S 9-N
  • camptothecin compounds can be found in Garcia-Carbonero, et al., Clin. Cancer Res. (March 2002) 8: 641-661. Examples of camptothecin compounds can also be found in U.S. Pat. No. 4,604,463, No. 6,403,569, and No.
  • the camptothecin compound can be administered from one month before administration of the virus until one month after administration of the virus.
  • the camptothecin compound and the virus are administered to the subject within a single twenty-four hour period; or the camptothecin compound is administered from twenty-four hours to one month, preferably from twenty-four hours to one week, before administration of the virus; or the camptothecin compound is administered to the subject from twenty-four hours to one month, preferably from twenty-four hours to one week, after administration of the virus.
  • the dosing and administration techniques and schedules for camptothecins and anti-cancer viruses are known in the art (See, e.g.
  • Irinotecan is usually administered to human patients in a dosage amount of from 62.5 to 125 mg/m 2 four times per week, or more preferably 80 to 125 mg/m 2 four times per week; or from 300 to 350 mg/m 2 once every three weeks, or more preferably 300 to 350 mg/m 2 once every three weeks.
  • any antibody against epidermal growth factor receptor can be utilized.
  • Chimeric and humanized monoclonal antibodies are preferred.
  • suitable anti-EGF antibodies include cetuximab (tradename: ERBITUX), ABX-EGF, MDX-447, h-R3, and EMD-7200 (see Mendelsohn J and Baselga J, “Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer”, 2004 J Clin Oncol 21:2787-2799).
  • Cetuximab is preferably administered to human patients intravenously, and is usually administered in an initial intravenous infusion of from 200 to 400 mg/m 2 , followed approximately weekly thereafter by subsequent infusions of from 125 to 250 mg/m 2 .
  • the subject that is treated in accordance with this invention can be either a human subject or a non-human mammalian subject.
  • any neoplasm can be treated, including but not limited to the following: rectal cancer, pelvic cancer, colon cancer, lung cancer, breast cancer, prostate cancer, glioblastoma, renal cancer, pancreatic cancer, head and neck cancer, endometrial cancer, neuroblastoma, carcinoid, melanoma, ovarian cancer, sarcoma, cancer of the gastro-esophageal junction, gastric cancer, esophageal cancer, liver cancer, and cervical cancer.
  • monitoring the treatment is not an essential aspect of the invention, there are techniques for measuring the therapeutic effects of the treatment. These include, measuring the size of the tumor after administration of the virus, and a decrease in tumor size is a positive result.
  • the NDV is a triple-plaque purified MK107, which is an attenuated (mesogenic) version of Newcastle Disease Virus, described more fully in International Patent Publication WO 00/62735, published Oct. 26, 2000 (Pro-Virus, Inc.). The entire content of WO 00/62735 is hereby incorporated herein by reference.
  • mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells. Five days later when the subcutaneous tumors were approximately 100 mm 3 in size, groups of animals were treated intraperitoneally with irinotecan (25 mg/kg) or vehicle. Two days later animals were treated intravenously with either NDV (6 ⁇ 10 6 plaque forming units, PFU) or vehicle. The incidence of complete tumor regression (CR, 100% tumor reduction) was much higher in the group receiving both irinotecan and NDV (60%) than either irinotecan alone (30%) or NDV alone (0%); see Table 1. TABLE 1 Treatment of tumor-bearing mice with irinotecan 2 days before treatment with NDV yields greater complete tumor responses than either agent alone. Treatment Number of Mice CR, % Irinotecan 10 30% NDV 10 0% Both Irinotecan 10 60% and NDV Vehicle Control 10 0%
  • mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells. Seven days later when the subcutaneous tumors were approximately 125 mm 3 in size, groups of animals were treated intraperitoneally with irinotecan (25 mg/kg) or vehicle and then approximately one hour later they were treated intravenously with either NDV (6 ⁇ 10 6 plaque forming units, PFU) or vehicle.
  • NDV plaque forming units
  • the incidence of complete tumor regression was much higher in the group receiving both irinotecan and NDV (90%) than either irinotecan alone (50%) or NDV alone (0%), see Table 2.
  • Treatment of tumor bearing mice with irinotecan the same day as treatment with NDV yields greater complete tumor responses than either agent alone. Treatment Number of Mice CR, % Irinotecan 10 50% NDV 10 0% Both Irinotecan 10 90% and NDV Vehicle Control 10 0%
  • mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells. Seven days later when the subcutaneous tumors were approximately 387 mm 3 in size, groups of animals were intravenously with either NDV (6 ⁇ 10 6 plaque forming units, PFU) or vehicle. Two days later, the mice were then treated with treated intraperitoneally with irinotecan (25 mg/kg) or vehicle. The incidence of complete tumor regression (CR, 100% tumor reduction) was much higher in the group receiving both irinotecan and NDV (70%) than either irinotecan alone (10%) or NDV alone (0%), see Table 3. TABLE 3 Treatment of tumor bearing mice with irinotecan two days after treatment with NDV yields greater complete tumor responses than either agent alone. Treatment Number of Mice CR, % Irinotecan 10 10% NDV 10 0% Both Irinotecan 10 70% and NDV Vehicle Control 10 0%
  • NDV treatment consist of six total intravenous treatments given at three times per week for two weeks followed by a one week rest period (see Table 4 below).
  • the first dose of each cycle consists of 12 to 24 billion PFU/m 2 (administered over 3 hours for course 1 and over 1 hour for all other courses) followed by additional doses of between 24 to 48 billion PFU/m 2 (each dose administered over 1 hour).
  • Irinotecan is given for four consecutive weeks on a weekly basis beginning during week 3 or 4 of cycle 1 followed by two weeks without irinotecan therapy (As an example, see Table 4 below).
  • NDV treatment consist of six total intravenous treatments given at three times per week for two weeks followed by a one week rest period (see Table 5 below).
  • the first dose of six consists of 12 to 24 billion PFU/m 2 (administered over 3 hours for course 1 and over 1 hour for all other courses) followed by a additional doses of 24 to 48 billion PFU/m 2 (each dose administered over 1 hour).
  • Patients begin their irinotecan therapy during week 3 and are given one dose every 3 weeks (See Table 5 below). Additional 3 week courses of both NDV and irinotecan are given to the patients. TABLE 5 Combination of treatment of NDV using irinotecan given once every 3 wks.
  • Cycles of treatment are repeated every 3 weeks.
  • Cancer patients are treated with both NDV and irinotecan as in examples 4 and 5, except that they additionally receive treatment with cetuximab [ERBITUX, a monoclonal antibody (mAb) against the epidermal growth factor receptor (EGFR)].
  • cetuximab dosing begins on week 3 or week 4.
  • the cetuximab dose is 200 to 400 mg/m 2 for the first intravenous (IV) infusion [administered as a 120 minute IV infusion (with a maximal infusion rate of 5 mL/min)] then 125 to 250 mg/m 2 [infused IV over 60 minutes] administered weekly thereafter.
  • IV intravenous
  • Some patients may also receive an initial test dose of cetuximab of 20 mg.
  • Diphendydramine (50 mg IV) is commonly given to help lessen any infusion reactions due to cetuximab.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
US11/568,228 2004-04-27 2005-04-26 Cancer treatment using viruses and camptothecins Abandoned US20070207149A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/568,228 US20070207149A1 (en) 2004-04-27 2005-04-26 Cancer treatment using viruses and camptothecins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56563104P 2004-04-27 2004-04-27
PCT/US2005/014144 WO2005113018A2 (en) 2004-04-27 2005-04-26 Cancer treatment using viruses and camptothecins
US11/568,228 US20070207149A1 (en) 2004-04-27 2005-04-26 Cancer treatment using viruses and camptothecins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014144 A-371-Of-International WO2005113018A2 (en) 2004-04-27 2005-04-26 Cancer treatment using viruses and camptothecins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/076,485 Continuation US20140065140A1 (en) 2004-04-27 2013-11-11 Cancer treatment using viruses and camptothecins

Publications (1)

Publication Number Publication Date
US20070207149A1 true US20070207149A1 (en) 2007-09-06

Family

ID=35428865

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/568,228 Abandoned US20070207149A1 (en) 2004-04-27 2005-04-26 Cancer treatment using viruses and camptothecins
US14/076,485 Abandoned US20140065140A1 (en) 2004-04-27 2013-11-11 Cancer treatment using viruses and camptothecins
US15/195,200 Active US9844574B2 (en) 2004-04-27 2016-06-28 Cancer treatment using viruses and camptothecins

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/076,485 Abandoned US20140065140A1 (en) 2004-04-27 2013-11-11 Cancer treatment using viruses and camptothecins
US15/195,200 Active US9844574B2 (en) 2004-04-27 2016-06-28 Cancer treatment using viruses and camptothecins

Country Status (14)

Country Link
US (3) US20070207149A1 (zh)
EP (1) EP1744780B1 (zh)
JP (2) JP5170741B2 (zh)
KR (1) KR20070008710A (zh)
CN (1) CN1946421B (zh)
AU (1) AU2005244768B2 (zh)
CA (1) CA2562904C (zh)
HK (1) HK1096583A1 (zh)
IL (1) IL178492A (zh)
MX (1) MXPA06012145A (zh)
NZ (1) NZ550430A (zh)
RU (2) RU2408387C2 (zh)
WO (1) WO2005113018A2 (zh)
ZA (1) ZA200608119B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193419A1 (en) * 2005-07-14 2008-08-14 Wellstat Biologics Corporation Cancer Treatment Using Viruses, Fluoropyrimidines and Camptothecins
US20110318430A1 (en) * 2008-12-18 2011-12-29 New York University Tumor therapy with antitumor agents in combination with sindbis virus-based vectors
US9844574B2 (en) 2004-04-27 2017-12-19 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2388315B1 (en) 2005-03-07 2014-05-21 The University of Western Ontario Use of a Myxoma virus that does not express functional M135R for therapeutic treatment
KR20090014364A (ko) 2006-06-01 2009-02-10 로바츠 리서치 인스티튜트 암 치료용 점액종 바이러스 변이종
WO2008043576A1 (en) * 2006-10-13 2008-04-17 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
ATE539148T1 (de) 2009-11-30 2012-01-15 United Cancer Res Inst Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs
RU2456002C1 (ru) * 2011-03-16 2012-07-20 Алексей Владимирович Дубищев Мочегонное средство
WO2015023551A1 (en) * 2013-08-13 2015-02-19 Bionumerik Pharmaceuticals, Inc. Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604463A (en) * 1983-07-14 1986-08-05 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US6403569B1 (en) * 1999-04-29 2002-06-11 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US20020071832A1 (en) * 2000-06-01 2002-06-13 Yuman Fong Use of mutant herpes viruses and anticancer agents in the treatment of cancer
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US20020168344A1 (en) * 2001-02-20 2002-11-14 Oncolytics Biotech, Inc. Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US20030068307A1 (en) * 2000-03-24 2003-04-10 De-Chao Yu Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US20040253272A1 (en) * 2001-08-02 2004-12-16 Yasufumi Kaneda Process for producing inactivated virus envelopes
US20050147591A1 (en) * 1995-10-06 2005-07-07 Hallahan Dennis E. Methods and compositions for viral enhancement of cell killing
US7056689B1 (en) * 1993-04-30 2006-06-06 Wellstat Biologics Corporation Methods of treating and detecting cancer using viruses
US20060165656A1 (en) * 2002-11-01 2006-07-27 Seiji Yamamoto Medicinal preparation having chemotherapeutic encapsulated therein
US7223389B2 (en) * 2001-09-12 2007-05-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of cancer
US20070128170A1 (en) * 2001-09-12 2007-06-07 Zichria Zakay-Rones Compositions of ndv and methods of use thereof for treatment of cancer
US7279333B2 (en) * 2000-02-02 2007-10-09 Anges, Mg, Inc. Virus envelope vector for gene transfer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
EA001400B1 (ru) 1995-11-02 2001-02-26 Глаксо Веллкам Инк. Способ получения производных камптотецина
GB9600438D0 (en) 1996-01-10 1996-03-13 Pharmacia Spa Hexacyclic camptothecin analogues, and process for preparing them
GB9601779D0 (en) 1996-01-30 1996-04-03 Pharmacia Spa 9, 10 Disubstituted camptothecin derivatives
GB9702807D0 (en) 1997-02-12 1997-04-02 Pharmacia & Upjohn Spa Alkynyl-substituted camptothecins and process for their preparation
GB9715821D0 (en) 1997-07-25 1997-10-01 Pharmacia & Upjohn Spa Amidino-camptothecin derivatives
GB9721070D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
IL141232A0 (en) 1998-08-05 2002-03-10 Aventis Pharma Sa Use of camptothecin derivatives, with reduced gastrointestinal toxicity
EP1044977B1 (en) 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
WO2000054795A1 (en) * 1999-03-15 2000-09-21 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
HUP0302278A3 (en) * 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
JP2003525234A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
BR0109272A (pt) 2000-03-17 2004-06-29 Cell Therapeutics Inc Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
GB0008928D0 (en) 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
MXPA02011218A (es) * 2000-05-15 2004-08-19 Celgene Corp Composiciones y metodos para el tratamiento de cancer.
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
EP1408975A2 (en) * 2001-07-23 2004-04-21 Epidauros Biotechnologie AG Methods for the treatment of cancer with irinotecan based on cyp3a5
WO2005113013A2 (en) 2004-05-20 2005-12-01 Theravir Management L.P. Compositions of ndv and methods of use thereof for treatment of cancer
TW200306314A (en) 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
US6593334B1 (en) 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
ITRM20020306A1 (it) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
AU2003243380A1 (en) 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
AU2003243397A1 (en) 2002-06-03 2003-12-19 California Pacific Medical Center Homo-camptothecin derivatives
RU2314830C2 (ru) 2002-06-21 2008-01-20 Веллстат Байолоджикс Корпорейшн Введение терапевтических вирусов
US6759416B2 (en) 2002-08-06 2004-07-06 Panorama Research, Inc. Anticancer conjugates of camptothecin and unsaturated fatty acids
CA2562904C (en) * 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
EP1771174A1 (en) 2004-05-28 2007-04-11 Pfizer Products Inc. Method for treating abnormal cell growth
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604463A (en) * 1983-07-14 1986-08-05 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US7056689B1 (en) * 1993-04-30 2006-06-06 Wellstat Biologics Corporation Methods of treating and detecting cancer using viruses
US20050147591A1 (en) * 1995-10-06 2005-07-07 Hallahan Dennis E. Methods and compositions for viral enhancement of cell killing
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6403569B1 (en) * 1999-04-29 2002-06-11 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US7279333B2 (en) * 2000-02-02 2007-10-09 Anges, Mg, Inc. Virus envelope vector for gene transfer
US20030068307A1 (en) * 2000-03-24 2003-04-10 De-Chao Yu Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US20020071832A1 (en) * 2000-06-01 2002-06-13 Yuman Fong Use of mutant herpes viruses and anticancer agents in the treatment of cancer
US20020168344A1 (en) * 2001-02-20 2002-11-14 Oncolytics Biotech, Inc. Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
US20040253272A1 (en) * 2001-08-02 2004-12-16 Yasufumi Kaneda Process for producing inactivated virus envelopes
US7223389B2 (en) * 2001-09-12 2007-05-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of cancer
US20070128170A1 (en) * 2001-09-12 2007-06-07 Zichria Zakay-Rones Compositions of ndv and methods of use thereof for treatment of cancer
US20060165656A1 (en) * 2002-11-01 2006-07-27 Seiji Yamamoto Medicinal preparation having chemotherapeutic encapsulated therein
US7427395B2 (en) * 2002-11-01 2008-09-23 Genomidea Inc. Chemotherapeutic agent-incorporated pharmaceutical preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cats A. New developments in systemic chemotherapy in advanced colorectal cancer. Scand J Gastroenterol Suppl. 2003;(239):78-86. *
Ramanathan RK, Belani CP. Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin Oncol. 1997 Aug;24(4):440-54. *
Robert Lorence et al. Poster# 5428, AACR meeting, April 6-10, 2002 in San Francisco. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844574B2 (en) 2004-04-27 2017-12-19 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US20080193419A1 (en) * 2005-07-14 2008-08-14 Wellstat Biologics Corporation Cancer Treatment Using Viruses, Fluoropyrimidines and Camptothecins
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
US20110117060A1 (en) * 2005-07-14 2011-05-19 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
US20110318430A1 (en) * 2008-12-18 2011-12-29 New York University Tumor therapy with antitumor agents in combination with sindbis virus-based vectors

Also Published As

Publication number Publication date
ZA200608119B (en) 2008-05-28
AU2005244768A1 (en) 2005-12-01
WO2005113018A2 (en) 2005-12-01
AU2005244768B2 (en) 2011-06-09
US20140065140A1 (en) 2014-03-06
KR20070008710A (ko) 2007-01-17
US20160303175A1 (en) 2016-10-20
MXPA06012145A (es) 2007-01-31
CN1946421B (zh) 2013-07-17
IL178492A (en) 2010-06-30
IL178492A0 (en) 2007-02-11
RU2408387C2 (ru) 2011-01-10
US9844574B2 (en) 2017-12-19
CA2562904A1 (en) 2005-12-01
EP1744780A4 (en) 2009-08-05
EP1744780A2 (en) 2007-01-24
JP5170741B2 (ja) 2013-03-27
CN1946421A (zh) 2007-04-11
NZ550430A (en) 2009-06-26
EP1744780B1 (en) 2013-08-07
JP2007534761A (ja) 2007-11-29
CA2562904C (en) 2013-07-02
RU2010138887A (ru) 2012-03-27
HK1096583A1 (en) 2007-06-08
WO2005113018A3 (en) 2006-03-02
RU2006141654A (ru) 2008-06-27
JP2013047276A (ja) 2013-03-07

Similar Documents

Publication Publication Date Title
US9844574B2 (en) Cancer treatment using viruses and camptothecins
US20110117060A1 (en) Cancer treatment using viruses, fluoropyrimidines and camptothecins
AU2003243307B2 (en) Administration of therapeutic viruses
US7118740B1 (en) Method for limiting the growth of cancer cells using an attenuated measles virus
EP2579884B1 (en) Anti-tumor composition
Lange Evaluation of a novel, suicide gene-armed measles vaccine virus for the treatment of cholangiocarcinoma
LÖHR 19 Experimental treatment of pancreatic cancer M. LÖHR, F. HUMMEL, WH GÜNZBURG and B. SALMONS
KR20060011969A (ko) 치료적 바이러스를 이용한 간세포 암종의 치료 방법

Legal Events

Date Code Title Description
AS Assignment

Owner name: WELLSTAT BIOLOGICS CORPORATION, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LORENCE, ROBERT M.;ROBERTS, MICHAEL S.;REEL/FRAME:016509/0395

Effective date: 20050422

AS Assignment

Owner name: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE

Free format text: SECURITY AGREEMENT;ASSIGNOR:WELLSTAT BIOLOGICS CORPORATION;REEL/FRAME:031029/0801

Effective date: 20130801

AS Assignment

Owner name: PDL BIOPHARMA, INC., NEVADA

Free format text: SECURITY AGREEMENT;ASSIGNOR:WELLSTAT BIOLOGICS CORPORATION;REEL/FRAME:031288/0530

Effective date: 20130820

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: WELLSTAT BIOLOGICS CORPORATION, MARYLAND

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:055060/0338

Effective date: 20210108